ALDOA and metabolic dysfunction-associated steatotic liver disease: Interestingly, obese individuals with non-alcoholic fatty liver disease express increased levels of ALDOA and ENO compared to obese controls [69] and enhanced expression of glycolysis-related genes is associated with tumor immune resistance [70].